ALKS · Alkermes plc

The thesis

Alkermes plc funds a sleep-medicine and orexin pipeline from growing commercial sales, and the shares have rebounded from their October low without recovering the summer loss. The adjusted close of $43.48 on 21 October 2026 is 21.3% below the 52-week high of $55.22. The third-quarter report, expected around 28 October 2026, settles whether revenue still supports the story.

The narrative is maturing: the 17 June 2026 Vibrance-2 narcolepsy data and the 21 September 2026 ADHD data are public, and the shares fell 17.8% over three months through 21 October 2026. The adjusted close was $40.11 on 8 October 2026, so the shares have regained ground since. Conviction stays low because the next dated test is a revenue print, and the three-month trend is still down.

Bullish and bearish views on Alkermes plc

The bull case on Alkermes plc (ALKS), in brief: Sleep drug cleared its main trial. The bear case: The three-month trend is negative.

Bull case

• Sleep drug cleared its main trial. Alkermes reported on 17 June 2026 that alixorexton met both primary endpoints in the Vibrance-2 phase 2 study in narcolepsy type 2, with sustained wakefulness gains. The drug received orphan designations in the US and Europe on 15 June 2026.
• Second orexin drug shows an early signal. On 21 September 2026 Alkermes said median ADHD symptom-score reductions after 14 days of ALKS 7290 were 14.0 points at 20 mg and 19.0 points at 50 mg. A placebo-controlled phase 2 study is running, so the signal can be tested.
• Commercial sales still grow. Alkermes reported Q2 2026 revenue of $496.0 million on 28 July 2026, including $96.6 million from LUMRYZ. Coverage of the report put revenue up 27.2% from a year earlier, and the company kept full-year 2026 revenue guidance of $1.730–1.840 billion.
• Analyst targets sit above the price. Truist resumed coverage on 16 October 2026 with a Buy rating and a $55 target. Needham's target was $61 on 24 June 2026, TD Cowen's was $50 on 22 June 2026 and RBC's was $56 on 9 June 2026.
• Sleep-medicine data flow continues. Alkermes said on 13 October 2026 it will give two oral presentations and six posters at the ESRS 28th Congress, Sleep Europe 2026.

Bear case

• The three-month trend is negative. The adjusted close was $45.97 on 11 September 2026, $40.85 on 25 September 2026, $40.11 on 8 October 2026 and $43.48 on 21 October 2026. The shares fell 17.8% over three months through 21 October 2026, during a period of positive clinical news.
• ADHD data cannot prove efficacy. The phase 1b study enrolled 50 adults, 10 of them on placebo, and Alkermes said it was not powered to detect statistically significant differences between groups. The phase 2 week-four placebo comparison is the real test, and its date is unconfirmed.
• VIVITROL loses exclusivity soon. BofA's 29 June 2026 note dates loss of exclusivity to January 2027. VIVITROL brought in $124.5 million in Q2 2026, about a quarter of total revenue.
• Revenue guidance sets a hurdle. Alkermes guided Q3 2026 revenue to $450–470 million on 28 July 2026. A result below $450 million or a lower full-year range would weaken the commercial support.

Price setup

The adjusted close of $43.48 on 21 October 2026 sits 21.3% below the 52-week high of $55.22 and $3.37 above the 8 October 2026 close of $40.11. The 14-day relative strength index (RSI) was 61.7 on 21 October 2026, up from 34.8 on 8 October 2026 and 24.1 on 25 September 2026. The reading shows the selling has eased and buying has returned for now.

The 11 September 2026 close of $45.97 and the $45.76 pre-Vibrance-2 high lie above the current price. The 7 August 2026 reference close of $49.17 is further up. A move through those levels would show the rebound extending; a return toward $40 would show it failing.

Crowding evidence is limited to the event. Unusual Whales put the options-implied move around the report at roughly 14% as of 6 October 2026. No Form 4 insider sales or share issuance appear in recent filings.

Catalysts, next 30 days

• Date unconfirmed: phase 2 ALKS 7290 ADHD study. No readout date has been given; a result inside 30 days is not expected.

Elapsed catalysts

• ~28 October 2026, est.: Q3 2026 results. Alkermes reported Q3 2025 on 28 October 2025 and Q2 2026 on 28 July 2026. Truist's 16 October 2026 coverage lists 28 October 2026 before the market opens as the estimate, and the company has not confirmed it. The $450–470 million revenue guidance is the benchmark. (passed 9d ago)
• Date unconfirmed: Sleep Europe 2026 presentations. Alkermes announced two oral presentations and six posters on 13 October 2026. New alixorexton or LUMRYZ detail could come with them. (passed 24d ago)

What would change the view

The case breaks if third-quarter revenue falls below the $450 million guidance floor, or if Alkermes cuts the full-year range of $1.730–1.840 billion. Either result would show the commercial business no longer funds the orexin programme before VIVITROL loses exclusivity in January 2027.

A daily close below $36 would also end it, since that would put the shares far below the 8 October 2026 close of $40.11. A phase 2 ALKS 7290 result showing no benefit over placebo at week four would remove the second pipeline leg.

Revenue inside or above the $450–470 million range, with the full-year guidance kept, would strengthen the case.

What it trades with

Alkermes trades on its own sleep-drug and commercial-sales results more than on the broad biotech group. Other orexin-agonist developers, including Takeda and Centessa, report competing narcolepsy data, so their trial news can move Alkermes shares.

VIVITROL generic competition from January 2027 is a company-specific revenue risk. A one-day move around the report of the size options markets imply, roughly 14% per Unusual Whales on 6 October 2026, would exceed the rebound since 8 October 2026.